Coherus Oncology Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Coherus Oncology Inc 's ROA in the second quarter of 2026?
Coherus Oncology Inc recorded a cumulative net loss of $-132 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -42.25%.

However, within the Healthcare sector 510 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 73, from total ROA ranking in the first quarter of 2026 at 112.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-52.22 %	-28.31 %	-43.04 %	2.28 %	-34.88 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-132	186	168	155	180
Return On Assets (TTM)	-42.25 %	50.33 %	42.39 %	34.81 %	40.64 %
CHRS's Total Ranking	# 73	# 112	# 130	# 95	# 3773
Total Assets (TTM) in million	210	266	258	517	439
Seq. Total Assets Change	-21.07 %	2.97 %	-49.98 %	17.53 %	18.43 %
Seq. Net Income Change	-	-	-	-	-

CHRS's 5 Years Annual ROA >> Back to CHRS Management Effectiveness >> Compare CHRS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 69
Sector	# 511
Overall	# 3795

Return On Assets Statistics
High	Average	Low
50.33 %	-44.35 %	-150.19 %
		(Dec 31 2018)

Financial Statements
Coherus Oncology Inc 's Assets	$ 210 million	CHRS's Balance sheet
Coherus Oncology Inc 's Income	$ -21 million	Quarterly CHRS's Income Statement
CHRS's Income by Division		See CHRS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-42.4 %	-28.76 %	30.94 %	-29.22 %	-18.59 %
Total Assets in million	258	449	630	481	679
Y / Y Net Income Change	489.41 %	-	-	-	-
Net Income in million	168	29	-238	-292	-287
Annual Return On Assets	65.04 %	6.36 %	-37.78 %	-60.68 %	-42.26 %

CHRS's 5 Years Annual ROA >> Back to CHRS Management Effectiveness >> Compare CHRS ROA to its Competitors

Comment on CHRS's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 65.04 % compared to prior year, due to annual net income growth of 489.41 % to $168.02 million, and due to decline of value in Coherus Oncology Inc 's assets by -42.4 % to $258.34 million, compared to $258.34 a year before.

More Return On Assets Ratios
CHRS's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CHRS's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CHRS's Competitors
Subscribers only: Roa for Coherus Oncology Inc 's Suppliers
Subscribers only: Return On Assets for CHRS's Customers

You may also want to know
CHRS's Roi	CHRS's Inventory Turnover Ratio	CHRS's Growth Rates	CHRS's Dividend Comparisons
	CHRS's Profitability Ratios	CHRS's Asset Turnover Ratio	CHRS's Dividend Growth
CHRS's Roe	CHRS's Valuation Ratios	CHRS's Financial Strength Ratios	CHRS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-11T07:12:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.